Diffuse large B-cell lymphoma (DLBCL) continues to be treated with an expanding selection of antibody- and cell-based therapies. However, macrophage phagocytosis checkpoints represent a vital area of ongoing research aimed at enhancing treatment effectiveness.
By exploring an evidence-maturity framework that spans from established targets like CD47 to newer candidates such as CD200, researchers are gaining valuable insights into how macrophage regulation can be harnessed for immunotherapy.
Source Attribution: Article content originally reported by Qi; Shasha; Deng; Lu; Shan; Yao; Yuhong; Chen; Tao. Read original story coverage on Qi; Shasha; Deng; Lu; Shan; Yao; Yuhong; Chen; Tao →
